1847 vs Pharma-Bio Serv: revenue, profit, margins and growth compared
1847 brought in $48.3M of revenue in fiscal 2025, Pharma-Bio Serv $9M in fiscal 2025. Revenue changed by +207.3% at 1847 and -5.3% at Pharma-Bio Serv on the year before, so 1847 grew faster. 1847 kept 136.3% of its revenue as net profit, Pharma-Bio Serv -1.1%. Free cash flow was $3.1M at 1847 and -$221.5K at Pharma-Bio Serv.
Fiscal years as each company reports them; the two may end in different months.
Questions about 1847 and Pharma-Bio Serv
Which is bigger by revenue, 1847 or Pharma-Bio Serv?
1847 is bigger by revenue: $48.3M in fiscal 2025, against $9M for Pharma-Bio Serv in fiscal 2025.
Which keeps more of its revenue as profit, 1847 or Pharma-Bio Serv?
1847 had a net margin of 136.3% in fiscal 2025; Pharma-Bio Serv had -1.1% in fiscal 2025.
Which grew revenue faster, 1847 or Pharma-Bio Serv?
In their latest fiscal years revenue changed by +207.3% at 1847 and -5.3% at Pharma-Bio Serv.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.